Amyris is an integrated renewable products company providing sustainable alternatives to petroleum-sourced products and rare materials. The Company uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules, flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as renewable ingredients in cosmetics, flavors, fragrances, polymers, lubricants and consumer products and also as renewable diesel and jet fuels.
Type
Public
HQ
Emeryville, US
Founded
2003
Size (employees)
440 (est)
Website
amyris.com
Amyris was founded in 2003 and is headquartered in Emeryville, US
Report incorrect company information

Key People/Management at Amyris

Kathleen Valiasek

Kathleen Valiasek

Chief Financial Officer
Eduardo Alvarez

Eduardo Alvarez

Chief Operating Officer
Joel Cherry

Joel Cherry

President, Research & Development
Cynthia Bryant

Cynthia Bryant

Senior Vice President Corporate Development & Collaborations
Caroline Hadfield

Caroline Hadfield

Senior Vice President, Personal Care
Jim Iacoponi

Jim Iacoponi

Senior Vice President, Business Operations & Optimization
Show more

Amyris Office Locations

Amyris has offices in Techno Park and Emeryville
Emeryville, US (HQ)
100 5885 Hollis St
Techno Park, BR
Rua John Dalton, 301 - Bloco B - Edificio 3
Show all (2)
Report incorrect company information

Amyris Financials and Metrics

Amyris Financials

Amyris's revenue was reported to be $143.45 m in FY, 2017
USD

Revenue (FY, 2017)

143.4 m

Gross profit (FY, 2017)

80.7 m

Gross profit margin (FY, 2017), %

56.3%

Net income (FY, 2017)

(72.3 m)

EBIT (FY, 2017)

(39.5 m)

Market capitalization (20-Apr-2018)

204.5 m

Cash (31-Dec-2017)

57.1 m

EV

246.2 m
Amyris's current market capitalization is $204.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

41.1 m43.3 m34.2 m67.2 m143.4 m

Revenue growth, %

5%(21%)97%

Cost of goods sold

38.3 m33.2 m37.4 m56.7 m62.7 m

Gross profit

2.9 m10.1 m(3.2 m)10.5 m80.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

7 m6 m9.3 m16.3 m7.9 m7.8 m8.6 m8.8 m9.6 m26.5 m13 m25.7 m24.2 m

Cost of goods sold

8.3 m6.2 m7.5 m10.1 m6.6 m11 m8.5 m11.2 m7.9 m14.9 m12.8 m17.3 m17.6 m

Gross profit

(1.3 m)(195 k)1.8 m6.2 m1.2 m(3.1 m)136 k(2.4 m)1.7 m11.7 m212 k8.4 m6.6 m

Gross profit Margin, %

(19%)(3%)19%38%16%(40%)2%(27%)18%44%2%33%27%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.9 m42 m12 m27.2 m57.1 m

Accounts Receivable

62.8 k33.6 m

Inventories

9.5 m6.5 m5.9 m6.2 m5.4 m

Current Assets

36.9 m73.6 m35.7 m59.1 m104.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

5.8 m47.8 m88.8 m67.2 m43.8 m10.9 m10.9 m7.8 m822 k582 k1.3 m5.1 m15.9 m

Accounts Receivable

24.9 m

Inventories

7.9 m11.1 m14.8 m16.7 m11.4 m11.1 m11.1 m7.6 m10 m7.9 m7.1 m5.7 m6.4 m

Current Assets

25.3 m73.8 m116.8 m102.9 m69.3 m36.1 m34.6 m27.7 m21.5 m21.1 m24.1 m41 m62.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(234.9 m)2.2 m(218.1 m)(97.3 m)(72.3 m)

Depreciation and Amortization

16.6 m15 m12.9 m11.4 m11.4 m

Inventories

(3.1 m)

Accounts Payable

(2.6 m)(3.2 m)4.4 m6.4 m5.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(24.2 m)16.4 m(35.5 m)(36.7 m)(52.3 m)(99.4 m)(176.1 m)(15.3 m)(28.9 m)(48.6 m)(37.4 m)

Depreciation and Amortization

6.8 m9.9 m2.9 m5.7 m8.6 m2.7 m

Accounts Payable

8.5 m5.8 m4.6 m3 m7.3 m(810 k)1.2 m4.3 m450 k

Cash From Operating Activities

(32.8 m)(52.2 m)(23.7 m)(39 m)(45.4 m)(25.4 m)
USDY, 2017

EV/EBIT

-6.2 x

EV/CFO

-2.4 x

Revenue/Employee

331.5 k

Financial Leverage

-0.8 x
Show all financial metrics
Report incorrect company information

Amyris News and Updates

Synthetic Biology 2017 Global Key Players –Amyris, Inc. (U.S.), DowDuPont (U.S.), GenScript USA Inc. (U.S.), Intrexon Corporation (U.S.), Integrated DNA Technologies (IDT) (U.S.) Market Analysis And Forecast To 2022

Wiseguyreports.Com Adds “Synthetic Biology-Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information